Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group.
Mughal, Tariq I
Sarris, A H
Seymour, J F
Mead, Graham M
Gianni, M A
Ferreri, A J M
Moreno, H Gomez
AffiliationDivision of Haematology/Medical Oncology, Peter MacCallum Cancer Institute, East Melbourne, Australia. email@example.com
MetadataShow full item record
AbstractPURPOSE: To determine clinical features and patterns of outcome of primary testicular diffuse large B-cell lymphomas (DLCL). PATIENTS AND METHODS: A retrospective international survey of 373 patients with primary testicular DLCL. RESULTS: Most patients presented with localized disease (stage I to II), and the median age at diagnosis was 66 years (range, 19 to 91 years). Anthracycline-based chemotherapy was administered to 255 patients (68%), and prophylactic intrathecal chemotherapy was given to 68 patients (18%); 133 patients (36%) received prophylactic scrotal radiotherapy. Median overall survival was 4.8 years, and median progression-free survival was 4 years. The survival curves showed no clear evidence of a substantial proportion of cured patients. A favorable international prognostic index score (IPI), no B-symptoms, the use of anthracyclines, and prophylactic scrotal radiotherapy were significantly associated with longer survival at multivariate analysis. However, even for patients with stage I disease and good-risk IPI, the outcome seems worse than what was reported for DLCL at other sites. At a median follow-up of 7.6 years, 195 patients (52%) had relapsed. Extranodal recurrence was reported in 140 cases. Relapses in CNS were detected in 56 patients (15%) up to 10 years after presentation. A continuous risk of recurrence in the contralateral testis was seen in patients not receiving scrotal radiotherapy. CONCLUSION: Testicular DLCL is characterized by a particularly high risk of extranodal relapse even in cases with localized disease at diagnosis. Anthracycline-based chemotherapy, CNS prophylaxis, and contralateral testicular irradiation seem to improve the outcome. Their efficacy is under evaluation in a prospective clinical trial.
CitationPatterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. 2003, 21 (1):20-7 J. Clin. Oncol.
JournalJournal of Clinical Oncology
- A clinical analysis of primary testicular diffuse large B-cell lymphoma in China.
- Authors: Cao B, Ji DM, Zhou XY, Zhao TP, Guo Y, Wang ZH, Cao JN, Hu XC, Hong XN
- Issue date: 2011 Sep
- First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
- Authors: Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E
- Issue date: 2011 Jul 10
- Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy.
- Authors: Touroutoglou N, Dimopoulos MA, Younes A, Hess M, Pugh W, Cox J, Cabanillas F, Sarris AH
- Issue date: 1995 Jun
- Consideration of aggressive therapeutic strategies for primary testicular lymphoma.
- Authors: Park BB, Kim JG, Sohn SK, Kang HJ, Lee SS, Eom HS, Kwon HC, Oh SY, Kang JH, Oh SJ, Shin HJ, Suh C, Kim JH, Kim HY, Kim K, Ryoo BY, Kim WS
- Issue date: 2007 Sep
- Testicular lymphoma--a retrospective, population-based, clinical and immunohistochemical study.
- Authors: Hasselblom S, Ridell B, Wedel H, Norrby K, Sender Baum M, Ekman T
- Issue date: 2004